目的探讨康艾注射液联合西妥昔单抗治疗晚期结直肠癌的临床疗效。方法选取2016年1月—2017年1月于青岛市商业职工医院进行治疗的晚期结直肠癌患者76例,根据治疗方案的差别分为对照组(38例)和治疗组(38例)。对照组患者静脉滴注西妥昔单...目的探讨康艾注射液联合西妥昔单抗治疗晚期结直肠癌的临床疗效。方法选取2016年1月—2017年1月于青岛市商业职工医院进行治疗的晚期结直肠癌患者76例,根据治疗方案的差别分为对照组(38例)和治疗组(38例)。对照组患者静脉滴注西妥昔单抗注射液,初始剂量为400 mg/(m2·周),滴速≤5 m L/min,滴注时间120 min,然后维持250 mg/(m^2·周)。治疗组在对照组的基础上静脉滴注康艾注射液,40 m L加入5%葡萄糖注射液250 m L,1次/d。两组患者均治疗6周。评价两组患者临床疗效,同时比较治疗前后两组患者生存质量改善情况、血清学指标和不良反应情况。结果治疗后,对照组的客观缓解率(ORR)和临床获益率(CBR)分别为28.95%%、52.63%,均分别显著低于治疗组的50.00%、73.68%,两组比较差异均具有统计学意义(P<0.05)。治疗后,对照组改善率为68.42%,显著低于治疗组的92.11%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清血管内皮生长因子(VEGF)、缺氧诱导因子-1α(HIF-1α)和基质金属蛋白酶-9(MMP-9)水平明显降低,而IL-2和干扰素-γ(IFN-γ)水平明显增高,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标改善情况明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论康艾注射液联合西妥昔单抗可有效提高晚期结直肠癌患者机体免疫功能,并可显著改善患者生活质量,具有一定的临床推广应用价值。展开更多
Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by ...Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by 0,0.3%,1%,3%and 10%KAI for 24,48 and 72 h,respectively.The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay.The apoptosis and cell cycle were evaluated by flow cytometry.Interleukin(IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction(qRT-PCR)and enzyme-linked immune sorbent assay(ELISA),respectively.The protein expression levels of cyclin A,cyclin E,cyclin B1,cyclin D1,p21,retinoblastoma(RB),protein kinase B(AKT),extracellular regulated protein kinases(ERK),signal transducer and activator of transcription(STAT)1 and STAT3 were detected by Western blot.Results:KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose-and time-dependent manner.After treated with KAI for 48 h,the proportion of G,phase was increased,expression level of cyclin D1 and phosphorylation-RB were down-regulated,whereas the expression of p21 was up-regulated(all P<0.01).Furthermore,48-h treatment with KAI decreased the phosphorylation level of STAT3,inhibited the mRNA and protein expressions of IL-6(all P<0.01).IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3%and 10%KAI,and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level(all P<0.01).Conclusion:KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G_(1)phase arrest in gastric cancer cells.展开更多
Software reliability for business applications is becoming a topic of interest in the IT community. An effective method to validate and understand defect behaviour in a software application is Fault Injection. Fault i...Software reliability for business applications is becoming a topic of interest in the IT community. An effective method to validate and understand defect behaviour in a software application is Fault Injection. Fault injection involves the deliberate insertion of faults or errors into software in order to determine its response and to study its behaviour. Fault Injection Modeling has demonstrated to be an effective method for study and analysis of defect response, validating fault-tolerant systems, and understanding systems behaviour in the presence of injected faults. The objectives of this study are to measure and analyze defect leakage;Amplification Index (AI) of errors and examine “Domino” effect of defects leaked into subsequent Software Development Life Cycle phases in a business application. The approach endeavour to demonstrate the phasewise impact of leaked defects, through causal analysis and quantitative analysis of defects leakage and amplification index patterns in system built using technology variants (C#, VB 6.0, Java).展开更多
Objective:To compare the safety and efficacy of Kang’ai injection combined with chemotherapy and chemotherapy alone in the treatment of non-small cell lung cancer.Methods:The related control and randomized studies fr...Objective:To compare the safety and efficacy of Kang’ai injection combined with chemotherapy and chemotherapy alone in the treatment of non-small cell lung cancer.Methods:The related control and randomized studies from 1966 to October 01,2022,were retrieved in the following databases:China National Knowledge Infrastructure,Wanfang databases,Value In Paper,SinoMed,PubMed,Embase and Cochrane Library.A comprehensive literature search was conducted in 7 electronic databases identifying all the relevant randomized controlled trials.Cochrane handbook 5.2.3 was applied to evaluate the quality of included trials,and the RevMan 5.3 software was used to analyze data and assess the publication bias.Results:From the 16 studies reviewed,a total of 1,398 patients were included.Compared with docetaxel+cis-platinum chemotherapy alone,Kang’ai injection combined with docetaxel+cis-platinum chemotherapy showed significant effects in improving clinical response rate(RR:1.40,95%confidence interval(CI)(1.25,1.58)),quality of life score(Karnofsky score)(RR:1.53,95%CI(1.32,1.78)),traditional Chinese medicine syndrome(RR:2.01,95%CI(1.43,2.83))and safety(RR:0.62,95%CI(0.54,0.71)),the differences were statistically significant.Conclusion:Kang’ai injection may increase the therapeutic effectiveness,improve the quality of life,and reduce the toxicity of chemotherapy in patients with non-small cell lung cancer.These results require confirmation by further rigorously designed randomized controlled trials(PROSPERO registration number:CRD42020176917).展开更多
Background:Combination therapy with traditional Chinese medicine and chemotherapy was proposed as a therapeutic strategy for non-small cell lung cancer patients.Therefore,we performed a systematic review and metaanaly...Background:Combination therapy with traditional Chinese medicine and chemotherapy was proposed as a therapeutic strategy for non-small cell lung cancer patients.Therefore,we performed a systematic review and metaanalysis of randomized controlled trials to assess effects of this combination therapy on non-small cell lung cancer.To evaluate the efficacy and safety of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the treatment of non-small cell lung cancer.Methods:A randomized controlled study of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the databases of China National Knowledge Infrastructure Database,WanFang Database,VIP Database,Sino-Med Database,PUBMED,EMBASE and Cochrane library was searched by computer.The literatures published from the database establishment to July 1,2020 were included in the search scope.After 2 evaluators independently evaluated and cross checked the quality of the study,Revman 5.3 was used to meta analyze the clinical effect of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy on patients with non-small cell lung cancer.Results:A total of 1,370 lung cancer patients were included in 20 RCTs.The results of meta-analysis showed that there were significant differences between the 2 groups in clinical efficacy(RR=1.32,95%CI(1.20,1.44)),quality of life(RR=1.44,95%CI(1.32,1.57)),immune function(MD=0.53,95%CI(0.23–0.83)),adverse reactions(RR=0.49,95%CI(0.41,0.58)).Conclusion:The Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy is effective and safe in the treatment of non-small cell lung cancer,and has great prospects for further development.However,the quality of evidence was very low-to-moderate.Considering the poor quality of evidence,we are not very confident in the results.We look forward to more research and update results in the future and improve the evidence quality.展开更多
Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,...Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,Cochrane Library and EMBASE were searched to collect the randomized controlled trials(RCTs)of Kang-ai injection,combined with chemotherapy versus chemotherapy alone for the treatment of ovarian cancer.The retrieval time was from the database setup to December 20,2018.After two researchers independently screened the researches,extracted data and evaluated the risk of the included studies,the RevMan 5.3 software was used for analysis.A total of 8 RCTS were included.Results:Results showed that patients in Kang-ai injection combined with chemotherapy group were superior to the conventional chemotherapy group patients in total effective rate[RR=1.31,95%CI(1.11,1.54),P=0.001],quality of life[RR=1.69,95%CI(1.35,2.13),P<0.001],leukopenia[RR=0.63,95%CI(0.51,0.77),P<0.001],nausea and vomiting[RR=0.41,95%CI(0.24,0.70),P=0.001],decreased hemoglobin[RR=0.50,95%CI(0.28,0.88),P=0.002],and thrombocytopenia[RR=0.45,95%CI(0.24,0.85),P=0.01].Conclusion:Kang-ai injection combined with chemotherapy for ovarian cancer is better than chemotherapy alone in improving total effective rate and quality of life,reducing the incidence of adverse reactions.Limited by the number and quality of included studies,the above conclusions are yet to be verified by more high-quality studies.展开更多
Background:To predict the effective targets of Kang’ai injection and analyze the pharmacological mechanism for the treatment of breast cancer based on the method of network pharmacology.Methods:The Traditional Chines...Background:To predict the effective targets of Kang’ai injection and analyze the pharmacological mechanism for the treatment of breast cancer based on the method of network pharmacology.Methods:The Traditional Chinese Medicine Systems Pharmacology database was used to predict the effective components of the Chinese patent medicine Kang’ai injection,and GeneCards database,Online Mendelian Inheritance in Man database and the Therapeutic Target Database were used to predict the therapeutic targets of breast cancer.Cytoscape 3.7.2 was used to construct active ingredient-disease-target network.String database and Cytoscape 3.7.2 software were used to draw the protein-protein interaction network and obtain the core target.Bioconductor and R language were used to analyze the effective action target for gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.Results:There were 42 effective active ingredients in the Chinese patent medicine Kang’ai injection,which acted on 105 targets,and it had 32 components that acted on 96 targets associated with breast cancer.The target regulates various biological processes such as inflammation,angiogenesis,apoptosis and cell proliferation,and regulates pathways such as PI3K-Akt signaling pathway,MAPK signaling pathway,AGE-RAGE signaling pathway in diabetic complications and thyroid hormone signaling pathway through gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis.Conclusion:The treatment of breast cancer with the Chinese patent medicine Kang’ai injection is a complex mechanism process with multiple targets,multiple pathways,and multiple choices,which provides a theoretical basis for the further extraction of effective components in the treatment of breast cancer.展开更多
Objective: To study the effects of Kang Ai injection + conventional chemotherapy on tumor markers, apoptotic molecules and immune response in patients with advanced non-small cell lung cancer (NSCLC). Methods: Patient...Objective: To study the effects of Kang Ai injection + conventional chemotherapy on tumor markers, apoptotic molecules and immune response in patients with advanced non-small cell lung cancer (NSCLC). Methods: Patients diagnosed as advanced NSCLC in our hospital during March 2015 - October 2017 were randomly divided into the experimental group receiving Kang Ai injection + conventional chemotherapy and the control group receiving conventional chemotherapy. The contents of tumor markers, apoptotic molecules and immunologic cytokines in serum and the contents of immune cells in peripheral blood were determined before and after chemotherapy. Results: after chemotherapy, the content of CEA, CYFRA21-1, SCC-Ag, GDF15 and Livin in the serum of the two groups decreased significantly, and the content of PDCD5, P53 and Bax increased significantly, and the content of CEA, CYFRA21-1, SCC-Ag, GDF15, Livin in the serum of the experimental group were lower than those of the control group, and the content of PDCD5, P53 and Bax were higher than those of the control group;the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of control group significantly decreased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly increased after chemotherapy;while the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of experimental group significantly increased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly decreased after chemotherapy. Conclusion: Kang Ai injection + conventional chemotherapy in the treatment of advanced NSCLC can more significantly decrease the serum tumor markers, regulate the secretion of apoptotic molecules and anti-tumor immune response than conventional chemotherapy.展开更多
文摘目的探讨康艾注射液联合西妥昔单抗治疗晚期结直肠癌的临床疗效。方法选取2016年1月—2017年1月于青岛市商业职工医院进行治疗的晚期结直肠癌患者76例,根据治疗方案的差别分为对照组(38例)和治疗组(38例)。对照组患者静脉滴注西妥昔单抗注射液,初始剂量为400 mg/(m2·周),滴速≤5 m L/min,滴注时间120 min,然后维持250 mg/(m^2·周)。治疗组在对照组的基础上静脉滴注康艾注射液,40 m L加入5%葡萄糖注射液250 m L,1次/d。两组患者均治疗6周。评价两组患者临床疗效,同时比较治疗前后两组患者生存质量改善情况、血清学指标和不良反应情况。结果治疗后,对照组的客观缓解率(ORR)和临床获益率(CBR)分别为28.95%%、52.63%,均分别显著低于治疗组的50.00%、73.68%,两组比较差异均具有统计学意义(P<0.05)。治疗后,对照组改善率为68.42%,显著低于治疗组的92.11%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清血管内皮生长因子(VEGF)、缺氧诱导因子-1α(HIF-1α)和基质金属蛋白酶-9(MMP-9)水平明显降低,而IL-2和干扰素-γ(IFN-γ)水平明显增高,同组比较差异具有统计学意义(P<0.05);且治疗组上述指标改善情况明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论康艾注射液联合西妥昔单抗可有效提高晚期结直肠癌患者机体免疫功能,并可显著改善患者生活质量,具有一定的临床推广应用价值。
基金Supported by National Science and Technology Major Project of the Ministry of Science and Technology of China(No.2017ZX09304025)Construction Program of Clinical Cooperation Ability of Chinese and Western Medicine for Major and Difficult Diseases(No.2019-163)+2 种基金the Key Research and Development Program of Liaoning Province(No.2018225060)Science and Technology Plan Project of Liaoning Province(No.2016007010)Science and Technology Plan Project of Shenyang City(No.19-112-4-099)。
文摘Objective:To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection(KAI)in gastric cancer cells.Methods:Gastric cancer cell lines MGC803 and BGC823 were treated by 0,0.3%,1%,3%and 10%KAI for 24,48 and 72 h,respectively.The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide(MTT)assay.The apoptosis and cell cycle were evaluated by flow cytometry.Interleukin(IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction(qRT-PCR)and enzyme-linked immune sorbent assay(ELISA),respectively.The protein expression levels of cyclin A,cyclin E,cyclin B1,cyclin D1,p21,retinoblastoma(RB),protein kinase B(AKT),extracellular regulated protein kinases(ERK),signal transducer and activator of transcription(STAT)1 and STAT3 were detected by Western blot.Results:KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose-and time-dependent manner.After treated with KAI for 48 h,the proportion of G,phase was increased,expression level of cyclin D1 and phosphorylation-RB were down-regulated,whereas the expression of p21 was up-regulated(all P<0.01).Furthermore,48-h treatment with KAI decreased the phosphorylation level of STAT3,inhibited the mRNA and protein expressions of IL-6(all P<0.01).IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3%and 10%KAI,and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level(all P<0.01).Conclusion:KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G_(1)phase arrest in gastric cancer cells.
文摘Software reliability for business applications is becoming a topic of interest in the IT community. An effective method to validate and understand defect behaviour in a software application is Fault Injection. Fault injection involves the deliberate insertion of faults or errors into software in order to determine its response and to study its behaviour. Fault Injection Modeling has demonstrated to be an effective method for study and analysis of defect response, validating fault-tolerant systems, and understanding systems behaviour in the presence of injected faults. The objectives of this study are to measure and analyze defect leakage;Amplification Index (AI) of errors and examine “Domino” effect of defects leaked into subsequent Software Development Life Cycle phases in a business application. The approach endeavour to demonstrate the phasewise impact of leaked defects, through causal analysis and quantitative analysis of defects leakage and amplification index patterns in system built using technology variants (C#, VB 6.0, Java).
文摘Objective:To compare the safety and efficacy of Kang’ai injection combined with chemotherapy and chemotherapy alone in the treatment of non-small cell lung cancer.Methods:The related control and randomized studies from 1966 to October 01,2022,were retrieved in the following databases:China National Knowledge Infrastructure,Wanfang databases,Value In Paper,SinoMed,PubMed,Embase and Cochrane Library.A comprehensive literature search was conducted in 7 electronic databases identifying all the relevant randomized controlled trials.Cochrane handbook 5.2.3 was applied to evaluate the quality of included trials,and the RevMan 5.3 software was used to analyze data and assess the publication bias.Results:From the 16 studies reviewed,a total of 1,398 patients were included.Compared with docetaxel+cis-platinum chemotherapy alone,Kang’ai injection combined with docetaxel+cis-platinum chemotherapy showed significant effects in improving clinical response rate(RR:1.40,95%confidence interval(CI)(1.25,1.58)),quality of life score(Karnofsky score)(RR:1.53,95%CI(1.32,1.78)),traditional Chinese medicine syndrome(RR:2.01,95%CI(1.43,2.83))and safety(RR:0.62,95%CI(0.54,0.71)),the differences were statistically significant.Conclusion:Kang’ai injection may increase the therapeutic effectiveness,improve the quality of life,and reduce the toxicity of chemotherapy in patients with non-small cell lung cancer.These results require confirmation by further rigorously designed randomized controlled trials(PROSPERO registration number:CRD42020176917).
文摘Background:Combination therapy with traditional Chinese medicine and chemotherapy was proposed as a therapeutic strategy for non-small cell lung cancer patients.Therefore,we performed a systematic review and metaanalysis of randomized controlled trials to assess effects of this combination therapy on non-small cell lung cancer.To evaluate the efficacy and safety of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the treatment of non-small cell lung cancer.Methods:A randomized controlled study of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy in the databases of China National Knowledge Infrastructure Database,WanFang Database,VIP Database,Sino-Med Database,PUBMED,EMBASE and Cochrane library was searched by computer.The literatures published from the database establishment to July 1,2020 were included in the search scope.After 2 evaluators independently evaluated and cross checked the quality of the study,Revman 5.3 was used to meta analyze the clinical effect of the Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy on patients with non-small cell lung cancer.Results:A total of 1,370 lung cancer patients were included in 20 RCTs.The results of meta-analysis showed that there were significant differences between the 2 groups in clinical efficacy(RR=1.32,95%CI(1.20,1.44)),quality of life(RR=1.44,95%CI(1.32,1.57)),immune function(MD=0.53,95%CI(0.23–0.83)),adverse reactions(RR=0.49,95%CI(0.41,0.58)).Conclusion:The Chinese patent medicine Kang’ai injection adjunct with TP chemotherapy is effective and safe in the treatment of non-small cell lung cancer,and has great prospects for further development.However,the quality of evidence was very low-to-moderate.Considering the poor quality of evidence,we are not very confident in the results.We look forward to more research and update results in the future and improve the evidence quality.
文摘Objective:This study was conducted to evaluate the clinical efficacy and safety of Kang-ai injection combined with chemotherapy in the treatment of ovarian cancer.Methods:the databases of VIP,CNKI,WanFang,CBM,Pub Med,Cochrane Library and EMBASE were searched to collect the randomized controlled trials(RCTs)of Kang-ai injection,combined with chemotherapy versus chemotherapy alone for the treatment of ovarian cancer.The retrieval time was from the database setup to December 20,2018.After two researchers independently screened the researches,extracted data and evaluated the risk of the included studies,the RevMan 5.3 software was used for analysis.A total of 8 RCTS were included.Results:Results showed that patients in Kang-ai injection combined with chemotherapy group were superior to the conventional chemotherapy group patients in total effective rate[RR=1.31,95%CI(1.11,1.54),P=0.001],quality of life[RR=1.69,95%CI(1.35,2.13),P<0.001],leukopenia[RR=0.63,95%CI(0.51,0.77),P<0.001],nausea and vomiting[RR=0.41,95%CI(0.24,0.70),P=0.001],decreased hemoglobin[RR=0.50,95%CI(0.28,0.88),P=0.002],and thrombocytopenia[RR=0.45,95%CI(0.24,0.85),P=0.01].Conclusion:Kang-ai injection combined with chemotherapy for ovarian cancer is better than chemotherapy alone in improving total effective rate and quality of life,reducing the incidence of adverse reactions.Limited by the number and quality of included studies,the above conclusions are yet to be verified by more high-quality studies.
基金This research was funded by Science and Technology Program of Guangzhou(Nos.201803010051).
文摘Background:To predict the effective targets of Kang’ai injection and analyze the pharmacological mechanism for the treatment of breast cancer based on the method of network pharmacology.Methods:The Traditional Chinese Medicine Systems Pharmacology database was used to predict the effective components of the Chinese patent medicine Kang’ai injection,and GeneCards database,Online Mendelian Inheritance in Man database and the Therapeutic Target Database were used to predict the therapeutic targets of breast cancer.Cytoscape 3.7.2 was used to construct active ingredient-disease-target network.String database and Cytoscape 3.7.2 software were used to draw the protein-protein interaction network and obtain the core target.Bioconductor and R language were used to analyze the effective action target for gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.Results:There were 42 effective active ingredients in the Chinese patent medicine Kang’ai injection,which acted on 105 targets,and it had 32 components that acted on 96 targets associated with breast cancer.The target regulates various biological processes such as inflammation,angiogenesis,apoptosis and cell proliferation,and regulates pathways such as PI3K-Akt signaling pathway,MAPK signaling pathway,AGE-RAGE signaling pathway in diabetic complications and thyroid hormone signaling pathway through gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis.Conclusion:The treatment of breast cancer with the Chinese patent medicine Kang’ai injection is a complex mechanism process with multiple targets,multiple pathways,and multiple choices,which provides a theoretical basis for the further extraction of effective components in the treatment of breast cancer.
文摘Objective: To study the effects of Kang Ai injection + conventional chemotherapy on tumor markers, apoptotic molecules and immune response in patients with advanced non-small cell lung cancer (NSCLC). Methods: Patients diagnosed as advanced NSCLC in our hospital during March 2015 - October 2017 were randomly divided into the experimental group receiving Kang Ai injection + conventional chemotherapy and the control group receiving conventional chemotherapy. The contents of tumor markers, apoptotic molecules and immunologic cytokines in serum and the contents of immune cells in peripheral blood were determined before and after chemotherapy. Results: after chemotherapy, the content of CEA, CYFRA21-1, SCC-Ag, GDF15 and Livin in the serum of the two groups decreased significantly, and the content of PDCD5, P53 and Bax increased significantly, and the content of CEA, CYFRA21-1, SCC-Ag, GDF15, Livin in the serum of the experimental group were lower than those of the control group, and the content of PDCD5, P53 and Bax were higher than those of the control group;the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of control group significantly decreased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly increased after chemotherapy;while the content of CD3+ and CD4+ cells in peripheral blood and the content of IFN-γ, IL-2 in serum of experimental group significantly increased, whereas the content of CD8+ cells in peripheral blood and the content of IL-4, IL-5 in serum significantly decreased after chemotherapy. Conclusion: Kang Ai injection + conventional chemotherapy in the treatment of advanced NSCLC can more significantly decrease the serum tumor markers, regulate the secretion of apoptotic molecules and anti-tumor immune response than conventional chemotherapy.
文摘目的：系统评价康艾注射液辅助放疗治疗恶性肿瘤的有效性和安全性,以为临床治疗提供循证参考。方法：计算机检索Cochrane图书馆、Pub Med、中国期刊全文数据库、中文科技期刊数据库和万方数据库,收集康艾注射液联合放疗（试验组）对比单纯放疗（对照组）治疗恶性肿瘤的随机对照试验（RCT）,提取资料并评价质量后,采用Rev Man 5.3统计软件进行Meta分析。结果：共纳入13项RCT,合计1 107例患者。Meta分析结果显示,试验组患者治疗有效率[RR=1.20,95%CI（1.10,1.32）,P〈0.000]、生活质量改善率[RR=1.62,95%CI（1.42,1.85）,P〈0.000]、体质量增加率[RR=1.39,95%CI（1.06,1.82）,P=0.02]、白细胞下降发生率[RR=0.34,95%CI（0.25,0.47）,P〈0.000]、胃肠道反应发生率[RR=0.27,95%CI（0.10,0.78）,P=0.02]、Ⅲ~Ⅳ级放射性损伤发生率[RR=0.35,95%CI（0.22,0.55）,P〈0.000]显著优于对照组,两组比较差异有统计学意义。结论：康艾注射液辅助放疗治疗恶性肿疗效与安全性均更好。受纳入研究方法学的局限性,该结论有待更多高质量、大样本、长期随访的RCT进一步验证。
